93 related articles for article (PubMed ID: 21266123)
1. [A clinical study of ProGRP as a new tumor marker for small cell lung cancer].
Yu B; Liu Q; Chen L
Zhongguo Fei Ai Za Zhi; 2003 Jun; 6(3):209-10. PubMed ID: 21266123
[TBL] [Abstract][Full Text] [Related]
2. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer.
Uchida K; Kojima A; Morokawa N; Tanabe O; Anzai C; Kawakami M; Eto Y; Yoshimura K
J Cancer Res Clin Oncol; 2002 Dec; 128(12):633-40. PubMed ID: 12474049
[TBL] [Abstract][Full Text] [Related]
3. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
4. ProGRP: a new biomarker for small cell lung cancer.
Molina R; Filella X; Augé JM
Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231
[TBL] [Abstract][Full Text] [Related]
5. [The clinical value of vascular endothelial growth factor in patients with small cell lung cancer].
Liu J; Zhu X
Zhongguo Fei Ai Za Zhi; 2007 Oct; 10(5):406-10. PubMed ID: 21126410
[TBL] [Abstract][Full Text] [Related]
6. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
7. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma.
Miyake Y; Kodama T; Yamaguchi K
Cancer Res; 1994 Apr; 54(8):2136-40. PubMed ID: 8174119
[TBL] [Abstract][Full Text] [Related]
8. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
[TBL] [Abstract][Full Text] [Related]
9. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
10. Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer.
Oh HJ; Park HY; Kim KH; Park CK; Shin HJ; Lim JH; Kwon YS; Oh IJ; Kim YI; Lim SC; Kim YC; Kim SH; Shin MG
J Thorac Dis; 2016 Sep; 8(9):2530-2537. PubMed ID: 27747005
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer.
Naumnik W; Chyczewska E; Izycki T; Ossolinska M
Rocz Akad Med Bialymst; 2004; 49 Suppl 1():88-90. PubMed ID: 15638385
[TBL] [Abstract][Full Text] [Related]
12. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
[No Abstract] [Full Text] [Related]
13. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
Bubanović G; Pavićević R; Franjević A
Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
[TBL] [Abstract][Full Text] [Related]
14. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
15. [The value of plasma pro-gastrin-releasing peptide, cytokeratin 19-fragments and carcinoembryonic antigen in patients with lung cancer].
Chen YJ; Jin WD; Yang GY; Zhou YL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct; 25(5):381-3. PubMed ID: 22338231
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations.
Kudo K; Ohyanagi F; Horiike A; Miyauchi E; Yanagitani N; Hoshi R; Satoh Y; Motoi N; Hamanaka W; Ishikawa Y; Mun M; Sakao Y; Okumura S; Nakagawa K; Horai T; Nishio M
Lung Cancer; 2011 Dec; 74(3):401-4. PubMed ID: 21529988
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of pro-gastrin releasing peptide promotes the cell proliferation and progression in small cell lung cancer.
Gong Z; Lu R; Xie S; Jiang M; Liu K; Xiao R; Shen J; Wang Y; Guo L
Biochem Biophys Res Commun; 2016 Oct; 479(2):312-318. PubMed ID: 27639644
[TBL] [Abstract][Full Text] [Related]
18. Decline in serum progastrin-releasing peptide predicts the response of patients with small cell lung cancer to chemotherapy.
Li M; Han D; Wang W; Zhang Y; Li D; Dai C; Qian L; Lin W
Oncol Lett; 2020 Dec; 20(6):301. PubMed ID: 33101495
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
20. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
